Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar;11(2):308-314.
doi: 10.1177/1932296816682762. Epub 2016 Dec 13.

Moving Toward a Unified Platform for Insulin Delivery and Sensing of Inputs Relevant to an Artificial Pancreas

Anneke Graf  1   2 , Sybil A McAuley  1   2 , Catriona Sims  2 , Johanna Ulloa  3 , Alicia J Jenkins  1   2   4 , Gayane Voskanyan  3 , David N O'Neal  1   2
Affiliations
Review

Moving Toward a Unified Platform for Insulin Delivery and Sensing of Inputs Relevant to an Artificial Pancreas

Anneke Graf et al. J Diabetes Sci Technol. 2017 Mar.

Abstract

Advances in insulin pump and continuous glucose monitoring technology have primarily focused on optimizing glycemic control for people with type 1 diabetes. There remains a need to identify ways to minimize the physical burden of this technology. A unified platform with closely positioned or colocalized interstitial fluid glucose sensing and hormone delivery components is a potential solution. Present challenges to combining these components are interference of glucose sensing from proximate insulin delivery and the large discrepancy between the life span of current insulin infusion sets and glucose sensors. Addressing these concerns is of importance given that the future physical burden of this technology is likely to be even greater with the ongoing development of the artificial pancreas, potentially incorporating multiple hormone delivery, glucose sensing redundancy, and sensing of other clinically relevant nonglucose biochemical inputs.

Keywords: artificial pancreas; closed loop; colocalization; continuous glucose monitoring; insulin delivery; unified platform.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The nonprofit employers of the authors AG, SAM, CS, AJJ, and DNO have received grant support from Medtronic for investigator-initiated studies. AJJ and DNO have previously received honoraria from Medtronic. JU and GV are employees of Medtronic.

Figures

Figure 1.
Figure 1.
Challenges and potential solutions in moving toward a unified insertion platform for an artificial pancreas.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Thabit H, Tauschmann M, Allen JM, et al. Home use of an artificial beta cell in type 1 diabetes. N Engl J Med. 2015;373(22):2129-2140. - PMC - PubMed
    1. Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013;369(3):224-232. - PubMed
    1. Maahs DM, Calhoun P, Buckingham BA, et al. A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1 diabetes. Diabetes Care. 2014;37(7):1885-1891. - PMC - PubMed
    1. Innovation Milestones. January 2015. Updated April 2015. http://www.medtronicdiabetes.com/about-medtronic-innovation/milestone-ti.... Accessed July 2016.
    1. Haidar A, Legault L, Messier V, Mitre TM, Leroux C, Rabasa-Lhoret R. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. Lancet Diabetes Endocrinol. 2015;3(1):17-26. - PubMed

Publication types

MeSH terms